Compare Nucor Corporation (NUE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nucor Corporation vs TG Therapeutics Inc — how do they compare? Nucor Corporation trades at $250.33 (market cap $55.84B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Nucor Corporation is far larger — about 6.8× TG Therapeutics Inc's market cap, and Nucor Corporation pays a 0.91% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nucor Corporation for 78 Days and TG Therapeutics Inc for 16 Days on average.
| NUE | TGTX | |
|---|---|---|
Market Cap | $55.84B | $8.16B |
Volume | 848,835 | 1,735,121 |
Sector | Basic Materials | Health |
52-Week High | $274.74 | $59.06 |
52-Week Low | $131.78 | $26.94 |
Typical Hold Time | 78 Days | 16 Days |
Enterprise Value | $60.25B | $8.37B |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $250.33, up 1.58% with a mixed technical picture showing bearish moving averages but neutral oscillators. The company delivered strong Q2 2026 earnings of $4.84 EPS, beating expectations, and projects higher Q3 earnings on improved steel pricing. Revenue has stabilized at $32.49B in 2025 after declines from 2022 peaks, with net margins improving to 7.99%. Analyst consensus remains positive with a $266.88 price target and 57.58% buy ratings.
Nucor presents a balanced opportunity with strong operational performance and shareholder returns through dividends, though facing headwinds from competitive pressures and cyclical steel demand. The stock's valuation appears reasonable with P/E of 19.64 and P/S of 1.56, but investors should monitor execution against Q3 guidance and industry capacity expansions.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
